Developing therapeutics targeting the Ephrin receptor
Our therapeutic development efforts center on targeting the Ephrin receptor for the treatment of neurodegenerative disease, proliferative neovascular disease and cancer. Our initial therapeutic focus is the treatment of certain eye diseases by modulation of Ephrin receptor dysregulation.
The team is led by experienced leaders with over 50 years of collective executive experience in biopharma, having contributed to the development of FDA-approved therapies and public companies with combined peak valuations of over $15 billion.
Focus
Our initial therapeutic focus is treating diseases of the eye, including glaucoma, dry age-related macular degeneration (AMD), proliferative diabetic retinopathy, and Stargardt disease. These conditions cause irreversible damage to retinal cells and retinal ganglion cells leading to vision loss.
By targeting Ephrin receptors in the eye, we aim to slow the progression of vision loss, while laying the groundwork for future therapeutic applications across broader neurodegenerative, neovascular and proliferative diseases.
Our Partners
We operate in partnership with two world-class academic institutions:
Bascom Palmer Eye Institute at the University of Miami
Weill Cornell Medical College at Cornell University
